Paper3906131
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
Boger J and 9 others. J Med Chem, 1985. Cited by 136 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. Papers, record 3906131. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3906131
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amino Acids | Major topic |
| Oligopeptides | Major topic |
| Renin Inhibitors | Major topic |
| Animals | |
| Binding, Competitive | |
| Blood Pressure | |
| Chemical Phenomena | |
| Chemistry | |
| Dogs | |
| Humans | |
| Kidney | |
| Macaca mulatta | |
| Mice | |
| Rabbits | |
| Rats | |
| Renin |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 32247750 | Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules. | Bioorg Med Chem | 2020 | https://conductscience.org/library/papers/32247750 | PubMed |
| 24900408 | Nonpeptidic lysosomal modulators derived from z-phe-ala-diazomethylketone for treating protein accumulation diseases. | ACS Med Chem Lett | 2012 | https://conductscience.org/library/papers/24900408 | PubMed |
| 22588582 | Exploring the substructural space of indole-3-carboxamide derivatives binding to renin: a novel active-site spatial partitioning approach. | J Mol Model | 2012 | https://conductscience.org/library/papers/22588582 | PubMed |
| 20440278 | New pharmacological treatments for improving renal outcomes in diabetes. | Nat Rev Nephrol | 2010 | https://conductscience.org/library/papers/20440278 | PubMed |
| 3334166 | Renin inhibitors. | Pharm Res | 1987 | https://conductscience.org/library/papers/3334166 | PubMed |
| 2407237 | The selectivity of statine-based inhibitors against various human aspartic proteinases. | Biochem J | 1990 | https://conductscience.org/library/papers/2407237 | PubMed |
| 2194200 | Development of a sensitive activity assay for high-volume evaluation of human renin inhibitory peptides in rat serum: results with U-71,038. | Pharm Res | 1990 | https://conductscience.org/library/papers/2194200 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3906131
GET https://conductscience.org/api/papers/v1/3906131/authors